Sheyu Li

Clinical diabetologist and endocrinologist in West China Hospital and Methodologist of clinical practice guideline in MAGIC China Center

[Sheyu Li @LisheyuSheyu]

This just published paper documents the excellent and, compared to alternatives, superior performance of the title and abstract screening tool of our CoreSR package.

https://t.co/OKwPEb6z7u

[The BMJ @bmj_latest]

How can you follow a structured approach for evaluating and managing hypomagnesaemia in community settings?

This Practice Pointer offers guidance #MedEd
https://t.co/2l5tfQv5go

[Sheyu Li @LisheyuSheyu]

Can #CGM strengthen #Prediabetes screening beyond HbA1c in Asian adults?
🩸 26% with HbA1c <5.7% had prediabetes
📈 CGM + HbA1c: AUC 0.876
🎯 Sensitivity: 76%–78%
🔗 https://t.co/8nBjkaaYZk

[Sheyu Li @LisheyuSheyu]

#DigitalDecisionSupport for #Perioperative Care of Patients With #Type2Diabetes—a timely call to translate real-time data into safer, more personalized surgical care. @jmirpub
🔗 https://t.co/D6x9TYzLY9

[Sheyu Li @LisheyuSheyu]

At JMIR Diabetes, we highlight stigma-free language training in #Type2Diabetes.

🗣️ Attitudes improved vs control (d=1.67)
✅ Helpful & actionable
⚠️ Pilot n=21; behavior not assessed

#diabetes #stigma #communication #physician
https://t.co/aySxlfq3ET

[The BMJ @bmj_latest]

Practice Pointer: Assessing, diagnosing, and managing hip osteoarthritis in primary care
https://t.co/t5ih76RsCk

[Sheyu Li @LisheyuSheyu]

🚨 More automation may bring more alarm burden. Among 838 adults with #T1D, 49% of AID users reported alarms several times/day vs 32% on CGM alone—plus more disruption, annoyance, ignored alerts & overcorrecting lows. Smarter alerts matter. 📲 https://t.co/hmIg6jzb9E

[Ash Paul @pash22]

Most obesity drugs do not improve quality of life or reduce cardiovascular risk, @LisheyuSheyu et al meta-analysis finds via @ingridtorjesen
https://t.co/9ZgaYXIFcu

[The BMJ @bmj_latest]

"Your training matters too, and you don’t deserve to miss out. If you don’t ask, you don’t get. Flag problems to your educational or clinical supervisor."

Tips on how to make time for training
https://t.co/bTz3oRfKmH

[MedPage Today @medpagetoday]

Variable weight-loss and cardiovascular benefits were seen with GLP-1 drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear. @LisheyuSheyu @HamidMerchant @MarieSpreckley @HamletGasoyan @MRothbergMD
https://t.co/lIHzXUOcXC

[The BMJ @bmj_latest]

I feel awful for failing an exam. What should I do?

It can be tempting to label yourself a failure, instead take time to reset before starting again, @Abi_Rimmer hears
https://t.co/Zgby8JM0qa

[Eric Topol @EricTopol]

Another new report confirms small excess risk of GLP-1 drugs for NAION, a vision-threatening condition (acronym for nonarteritic anterior ischemic optic neuropathy)
https://t.co/jhZXgTszJm

[Sheyu Li @LisheyuSheyu]

This guideline-informing systematic review showed massive and latest evidence for obesity treatment drugs.

[Arnav Agarwal @ArnavAgarwalMD]

Obesity pharmacotherapy is moving fast.

In our @bmj_latest NMA of 262 RCTs, tirzepatide & CagriSema produced the greatest weight loss, but benefits came with more adverse events. Few drugs showed CV benefits, and QoL did not meaningfully improve.

👉 https://t.co/OHh654QbRF

[Sheyu Li @LisheyuSheyu]

🩺 Chinese Consensus on Prolactinomas Just Released!
✍️36 evidence-based recommendations
👉Strong push for MDT
👉DA agonists still cornerstone
👉Endoscopic surgery raises
👉Tips for special cases
#Prolactinoma #PituitaryTumor #Neurosurgery #Endocrinology
https://t.co/KvWy2XZK1Z

[Arnav Agarwal @ArnavAgarwalMD]

Recently in @bmj_latest: living network meta-analysis of medications for type 2 diabetes across 869 RCTs and 493k participants.

Clearer evidence on cardiovascular, kidney, weight-loss benefits & drug-specific harms to support risk-stratified decisions.

https://t.co/NscvS2cYgA

[Sheyu Li @LisheyuSheyu]

Mapping recommendations for type 2 diabetes serves clinicians, patients and guideline adapters by cutting redundant summary of existed guidelines. #diabetes #guideline #GIN https://t.co/xWfjFxwddb

[Sheyu Li @LisheyuSheyu]

🌍 Global T2D Burden

📊 >500M adults affected worldwide
⚠️ Driven by obesity, sedentary lifestyle, aging
🌏 Fastest growth in Asia & LMICs

🔎 Key note:

Risks of CVD, CKD & cancer
Prevention via lifestyle change
Early detection & equitable care

🔗https://t.co/OD9sn1ulDq

[Sheyu Li @LisheyuSheyu]

Digital health for smoking cessation: the current future. https://t.co/oDp9Gr9Vid

[Arnav Agarwal @ArnavAgarwalMD]

ICYMI: a living #guideline on medications for #diabetes. 1st iteration recently out in @bmj_latest, accompanied by #SystematicReviews regarding benefits and harms, prognostic models, and patient values and preferences. #SGLT2i #GLP1RA #finerenone #tirzepatide #RapidRecommendation

[Alliance for Living Evidence (Alive) @AliveEvidence]

It’s been 6 months since we relaunched the Alive Learning Forum 🎉
We’d love your feedback!
Share your thoughts on what’s working, what can improve, and ideas for future topics/speakers. https://t.co/Z6hyrBSMkA

#AliveEvidence #LivingEvidence #AliveLearningForum